Introduction
Central to efforts to reduce the frequency of hospitalization in heart failure (HF) has been the need to identify clinical deterioration as early as possible, allowing for intervention to reduce hospitalizations. Standard advice for patients includes self-monitoring of weight and symptoms, but this is limited by patient understanding and has a low sensitivity.
and have the necessary early responsiveness to deterioration that is required. 5 Further supporting their role in this arena are the emerging data from clinical trials, summarized in a recent meta-analysis, outlining the potential value of serial NP testing in guiding treatment decisions in chronic HF. 6 This same meta-analysis suggests that the phenotype of HF and possible co-morbidities may influence the efficacy of NP-guided therapy. 6 Further information on this strategy is awaited from the recently completed GUIDE-IT trial, but its premature termination for futility might cast doubt on this approach and we await formal publication of this study. Furthermore, these trials usually employed relatively infrequent monitoring of NPs, potentially underestimating the benefit of such an approach. 7, 8 With this background, the HF Outpatient Monitoring Evaluation (HOME) study was designed as a randomized clinical trial to address whether daily BNP measurement integrated into a home health monitoring system improved outcomes compared to those managed with a home health management system without daily BNP and a third arm managed by routine care approach. The study set out to enrol high-risk patients characterized by reduced left ventricular ejection fraction.
Enrolment was terminated prematurely in December 2012 because of (i) low enrolment rate, (ii) low event rate in the primary endpoint, and (iii) the emerging belief that a formal algorithm for interpreting and acting upon changes in BNP trends and patterns was needed. Patients already enrolled in the study completed the full course of monitoring and the HOME study evolved into the largest observational study of monitoring of daily BNP samples, with approximately 12 500 daily BNP results from 107 subjects monitored for approximately 6 months per subject. Given that study arms did not significantly differ with regard to the primary endpoint, analysis of the pooled data as an observational cohort was justified. We report herein on the outcomes noted and information obtained on patterns of daily BNP and weight monitoring relative to clinical events.
Methods
Protocol HOME was planned as a prospective, multicentre, multinational, adaptive three-arm, randomized clinical study to investigate whether patients with HF using a home health monitoring system whose treatment was assisted by a daily BNP and weight measurement (BNP arm) would have improved clinical outcomes vs. subjects whose treatment was blinded to BNP (daily health management or DHM arm) and to subjects whose treatment was blinded to all monitoring results (standard of care or SOC arm). Secondary objectives of this study were to (i) determine the feasibility of frequent home BNP self-testing in this population, (ii) determine the dispersion of BNP and the optimal frequency of home BNP testing, and (iii) determine the changes in BNP concentrations that correlate with acute decompensated HF (ADHF).
Patient eligibility
Patient inclusion and exclusion criteria are reported in 
Inclusion criteria
• HFrEF (LVEF <40%) with at least one of the following: -ADHF admission within 30 days with BNP >300 pg/mL or NT-proBNP >1500 pg/mL -Seen in outpatient department with features of worsening heart failure (changing clinical status with need to change therapy or physical signs of volume overload, i.e. elevated JVP, S3, pulmonary rales, ankle oedema or significant weight gain of 3-5 lb over 2 days)
Exclusion criteria
• Unstable ischaemic episode • Heart transplant recipient or likely transplant recipient within 3 months of enrolment • Presence of left ventricular assist device • Inotrope-dependent • Surgical procedure or coronary revascularization within 3 months leading up to enrolment • Dialysis-dependent renal failure • Life expectancy anticipated to be less than 6 months • Taking investigational compound or partaking in another study • Unlikely to be effective in following investigators' instructions ADHF, acute decompensated heart failure; BNP, B-type natriuretic peptide; HFrEF, heart failure with reduced ejection fraction; JVP, jugular venous pressure; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
procedures were performed. Study subjects were trained to perform finger stick self-testing with the HeartCheck system (Alere Technologies Ltd., Stirling, Scotland), and a proficiency assessment was performed following one week (7 ± 2 days) of home testing to demonstrate retention of the training.
Study randomization
Successful completion of the proficiency assessment was followed by randomization. Failure to demonstrate proficiency resulted in subject withdrawal. All subjects were asked to provide daily information regarding weight, signs and symptoms, and to perform a daily finger stick BNP self-test, up until the end of the monitoring period.
All information was automatically uploaded via wireless transmission to the sponsor's encrypted web-based database where it was displayed to the medical staff in tabular and graphic form. For subjects in the BNP arm, all data including daily BNP values, weights and signs and symptoms of HF were available to the medical staff. For subjects in the DHM arm, daily weights and signs and symptoms of HF were available, but daily BNP values were withheld. For subjects in the SOC arm, daily BNP values, daily weights and signs and symptoms of HF were all withheld. The results of BNP testing were blinded to the patients in all arms of the study. consistent time each day, preferably at the time of weight measurement and before breakfast and any morning medications. Weight data were collected on scales that transferred data to the HeartCheck system via Bluetooth. The HeartCheck system prompted patients to answer five questions regarding symptoms of HF to provide a metric of their clinical status. The HeartCheck system had CE Mark for professional use at the start of the study and the competent authority in each participating country was informed of the study and the status of HeartCheck system at that time. The HeartCheck system later received CE Mark for patient self-testing at home.
Observation period and patient follow-up
The observation period was defined as the date of proficiency assessment (randomization) through to the date of the day 180 office visit, or the date the subject was lost to follow-up. Patients were reviewed at the study centre at day 30, 90 and 180 after randomization and/or at study withdrawal. At these visits, the following was performed: physical examination including body weight, medication analysis noting any changes in HF-related therapies and noting of any HF-related or cardiovascular clinical events, including any unplanned visits to a hospital or an outpatient clinic. Outcome data were collected throughout the observation period regardless of the patient's physical presence at the scheduled visits.
Treatment decisions
Prior to the commencement of the study, all investigators discussed approaches to changes in BNP and clinical status, but no defined protocol for intervention for any of these metrics was mandated, and treatment decisions were the sole responsibility of the local investigator.
Study endpoints
The primary endpoint was a composite of HF-related death, hospital admission due to ADHF, ADHF treated with intravenous diuretics in an emergency room, or equivalent ADHF treatment in an outpatient setting. Events counted towards the primary endpoint were adjudicated by an independent cardiologist who was blind to the home monitoring data.
Statistical analysis
An overview of the statistical approach is outlined below. A more detailed outline is provided in the Supplementary material online. The monitoring period was defined as the date of the first BNP measured within the observation period through 5 days past the last BNP measure, but not past the date the subject was lost to follow-up. In-hospital days (beyond the day of admission) were not eligible for the primary outcome and were excluded from the total exposure. predictor fBNP(t) in Poisson regression together with the time-varying weight gain. P-values ≤0.05 were considered statistically significant. The value of fBNP on the first day of the monitoring period is denoted fBNP(day1) and the ratio of fBNP(t) to fBNP(day1) is denoted as Ratio(t).
Results

Baseline characteristics and demographics
A total of 145 patients were enrolled ( Table 2 ) from nine sites in Europe, Australia and New Zealand. Enrolment commenced in May 2011 and was terminated in September 2012. There were 35, 34 and 38 evaluable subjects in BNP, DHM and SOC arms, respectively, encompassing 5746, 5564 and 6052 patient days.
There were 27 primary endpoint events distributed amongst patients as follows: 12 had a one event, six had two events, and one had three events. Their distribution among the four components of the primary endpoint is shown in Table 3 . Of the 27 primary events, there were 11, 6, and 10 observed in the BNP, DHM, and SOC arms, respectively (P = NS between groups). Relative to the SOC arm, the BNP arm had a hazard ratio of 1.16 [95% confidence interval (CI) 0.49-2.73] and the DHM arm had a hazard ratio of 0.65 (95% CI 0.24-1.80).
Patient capacity to measure and transmit BNP data
There were 38 unevaluable subjects, of whom 30 did not complete the first 7 days proficiency testing. Eight were randomized but withdrawn due to insufficient BNP testing (fewer than six study-related finger-stick tests). Throughout the monitoring period, BNP data transmission occurred on 12 049 of 17 362 monitored days compared to transmission of weight which occurred on 13 343 of monitored days.
BNP dispersion between measures
The intra-individual dispersion of BNP measures was analysed by inspection of the distribution of pairs of BNP values separated by time (in days). The dispersion in percent is a robust estimate of the coefficient of variation of the ratio (of the two measures). The dispersion is independent of the time course of the study and is only a function of the time difference between measures, and grows from 39.3% for 1 day between measures, to 57.7% for 60 days between measures, to 73.6% for 120 days between measures. A more detailed analysis of dispersion is presented in the Supplementary material online ( Figures S1 and S2) .
Weight gain
The frequency of weight gain of ≥5 lb over 5 days was 3.73% of patient days (648 days of weight gain out of 17 362 patient days of monitoring). However, only three of these days of weight gain corresponded to a primary event (sensitivity of 11.1%). The frequency of weight gain of ≥5 lb over 3 days was 2.09% of patient days and captured only a single primary event. We therefore used the lower threshold (≥5 lb over 5 days) in the risk model. of models is shown in Table 4 . The univariate model for fBNP resulted in a hazard ratio of 2.22 (95% CI 1.48-3.34) per unit natural log, i.e. when fBNP changes by a factor of 2.72 between any two patient days, the change is associated with a hazard ratio of 2.22. While the value of fBNP on the first day of the monitoring period (day 1) had a relatively weak hazard ratio of 1.46 (95% CI 0.96-2.21) per unit natural log, the ratio of fBNP to its value on day 1 had a relatively strong hazard ratio of 2.71 (95% CI 1.52-4.81) per unit natural log. The univariate model for weight gain resulted in a hazard ratio of 3.22 (95% CI 0.97-10.71) for a day of weight gain compared to a day without weight gain. The hazard ratio for fBNP did not change appreciably when adjusted for weight gain in a multivariate model. Looking at continuous values of weight gain (per lb) over a 5-day interval, or considering shorter, or longer intervals, or different thresholds of weight gain, did not improve the strength of this predictor. However, the hazard ratio for fBNP strengthened to 3.27 (95% CI 1.84-5.83) per unit natural log when adjusted for the initial value of fBNP.
Relationship of change in BNP to clinical events
The importance of the strengthening of fBNP when looked at in combination with fBNP(day 1) is reinforced by the last multivariate model in Table 4 , where Ratio(t) is the ratio of fBNP(t) to fBNP (day 1). This model shows that both Ratio(t) and fBNP(day 1) have significant adjusted hazard ratios, both of which have increased in strength relative to the univariate models. Patients who start out with high fBNP are at higher risk than patients who start out with low fBNP, but Ratio(t) is an independent risk predictor with a hazard ratio of 3.27 for each unit increase in the natural log.
Baseline characteristics were also considered. Each baseline characteristic in Table 1 was evaluated as a univariate predictor of primary events in Poisson regression. From this analysis, the The time-varying predictors are the natural log of fBNP and weight gain on each day of the monitoring period. Weight gain of ≥5 lb over 5 days was treated as a dichotomous predictor. The value of fBNP on the first day of the monitoring period is denoted fBNP(day1). The Ratio(t) is defined as fBNP(t)/fBNP(day1). The log is the natural log. The intercepts of the models are not shown.
statistically significant predictors (P < 0.05) were New York Heart Association class III, angina, coronary artery disease, prior myocardial infarction, pacemaker/implantable cardioverter-defibrillator, arrhythmia, chronic renal insufficiency, and insulin-requiring diabetes. Each of these predictors was then paired with time-varying fBNP in a set of two-predictor models. For each two-predictor model, the adjusted hazard ratio for fBNP was calculated and compared to the unadjusted (univariate) hazard ratio of 2.22 (95% CI 1.48-3.34) per unit natural log. The smallest adjusted hazard ratio for fBNP was 1.87 (95% CI 1.24-2.82) per unit natural log (when adjusted for a baseline history of angina). The largest adjusted hazard ratio for fBNP was 2.31 (95% CI 1.51-3.55) per unit natural log (when adjusted for a baseline history of insulin-requiring diabetes). It was concluded that adjusted and unadjusted hazard ratios were not significantly different because the point estimate of one fits within the CI of the other.
Explanation on how fBNP may be used to help predict risk of ADHF along with case histories outlining the utility of home BNP monitoring is provided in the Supplementary material online ( Figure S3 ).
Discussion
The data from the HOME study provide further important information on the potential role of patient-initiated home NP monitoring as a component of HF management. Consistent with the previously published HABIT trial, our results confirm that a routine HF population can readily and safely measure and transmit BNP values from home. intervals, an important observation providing insight into the natural history and unstable nature of the HF syndrome. Finally, our results provide for the first time information over a sufficiently long monitoring period, demonstrating that a calculated moving average value for BNP (fBNP) can predict emerging clinical problems and change in clinical status, independent of its baseline value. These data, along with the HABIT trial results, provide critical background information to design and perform a randomized clinical trial in which agreed changes in fBNP will trigger interventions and determine whether such an approach can have an impact on patient outcomes. Recurrent cardiac decompensation remains a challenge in HF care. A central issue is the need to identify early emerging deterioration. Whilst HF disease management that includes patient education on self-care has been shown to improve clinical outcomes, 13 more focused educational interventions have reported less favourable results.
14 However, it is clear that additional strategies are required, likely reflecting the lack of sensitivity of weight change and the late emergence of symptoms in the natural history of deterioration.
1 While work on invasive strategies such as monitoring of pulmonary pressures has been shown to be of benefit, 4 it is preferable that any additional surveillance method should be non-invasive, allowing broader reach and application.
Plasma BNP, measured at intervals of days, have been assessed as a tool to help guide therapeutic decisions in HF. 8 Over a dozen trials have been completed in this area providing variable results in terms of the effect of this strategy upon clinical outcomes but uniformly confirming the prognostic value of serial plasma BNP levels. The value of this approach is supported by recent meta-analyses of these studies, though we await the published results of the GUIDE-IT trial which is reported to have been a neutral study explaining its premature termination. 7, 15, 16 The HOME HF study takes this concept one step further by addressing the value of day-to-day NP assessment as an early warning metric for impending deterioration.
The HOME study was initially designed to assess the possible benefit of home BNP monitoring. However, as outlined in the Introduction, the decision for early termination of the HOME study was made for a number of reasons. Therefore, the study did not fulfil its original goal to further inform on the strategy of NP-guided therapy in HF with reduced ejection fraction (HFrEF), which remains a somewhat contentious issue as reflected by the current European Society of Cardiology guidelines. 17 Nonetheless, the absence of differences in endpoint rates among study arms allowed the pooling of data resulting in the largest observational study of daily BNP values over time (daily BNP values over 17 362 patient days of monitoring) and thereby provides important insights into several aspects of this approach, which will help design a planned randomized controlled trial.
BNP is a dynamic variable in HF patients, exhibiting large day-to-day fluctuations and cumulative trends that reflect biovariability, the unstable nature of the disease, and likely in addition its attendant co-morbidities.
18 -21 The HOME study provides further important information on this topic and confirms and extends key observations made previously in the HABIT study, 11 namely the high degree of variability between BNP measures separated by just a few days and increasing as the duration between measurements increases. Our results are also consistent with those of Meijers et al. 22 where in a stable HF population they found the intra-individual coefficient of variation for NT-proBNP was 21.8% at 3 weeks compared with 27.1% calculated at the same time in this study.
The moving average value of BNP, referred to as fBNP, correlates strongly with a patient's risk of ADHF. The hazard ratio for worsening ADHF as defined by the primary events was 2.22 (95% CI 1.48-3.34) per unit natural log of fBNP. The hazard ratio for fBNP did not change appreciably when adjusted for weight gain, or the baseline characteristics of the study population. Furthermore, the hazard ratio of time-varying fBNP strengthened when adjusted for the initial value of fBNP on the first day of monitoring (which was a relatively weak predictor on its own). Overall, the HOME study agrees qualitatively with the HABIT study 11 which reported a hazard ratio of 1.87 (95% CI 1.44-2.42) per unit change in log BNP. Acute rises in BNP were also examined in the HOME study and were found to be non-significant, consistent with the HFrEF subjects in the HABIT study.
12 These data provide further insight into how community NP monitoring might be of clinical value, even in the setting where its use to guide therapy in stable patients remains unproven. The data indicate that regular frequent monitoring independently predicts impending clinical deterioration, a very useful aid to clinical care, especially as a non-invasive approach it would be more practical and applicable on a wider scale than invasive monitoring. As noted, patient uptake and proficiency were acceptable, and likely could be improved further by additional coaching and family involvement.
While providing the largest database to date on home BNP monitoring, there are aspects of this study that need to be . Observations made may not be similarly applicable to the HF with preserved ejection fraction (HFpEF) cohort, though it is reassuring in this regard that metrics such as the within subject dispersion of BNP values were similar to the HABIT trial which did include patients with HFpEF. Additionally, the advent of sacubitril/valsartan as a therapeutic strategy in this cohort will produce debate on how best to use NP in following clinical status. 23 The results of the HOME study demonstrate that patient self-testing of BNP at home is feasible and relatively easy. The daily trends of BNP in HOME confirm ADHF risk can be monitored and that changes are associated with changes in risk of adverse HF-related events. These important natural history data provide sufficient background information to develop BNP monitoring algorithms to help guide therapeutic intervention.
Supplementary Information
Additional Supporting Information may be found in the online version of this article: Figure S1 . Dispersion of BNP measures vs. time between measures. Figure S2 . The evolution of fBNP as a box plot over subjects at weekly intervals (through 20 weeks) during the monitoring period. Figure S3 . Case examples of subjects with monitoring data (BNP and weight).
